Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 9,143 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Fibrosing Colonopathy
Interventions: ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy; Biological · Other
Lead sponsor: AbbVie; Industry
Eligibility: 0 Months to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 123
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more

Conditions: Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1)
Interventions: Lumasiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 0 Years to 5 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Rochester, Minnesota • Houston, Texas

Conditions: Leukemia, Lymphoma
Interventions: nelarabine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 7
States / cities: Duarte, California • Tampa, Florida • Bethesda, Maryland + 4 more

Conditions: Migraine
Interventions: Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Chemotherapy, Pembrolizumab, Ramucirumab; Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 566
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more

Conditions: Graft Versus Host Disease
Interventions: Prochymal®, Placebo, Standard of Care for GVHD; Biological · Drug
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 6 Months to 70 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 47
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more

Conditions: Hepatic Complication
Interventions: Cisplatin, Gemcitabine Hydrochloride, Quality-of-Life Assessment, Sirolimus; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Migraine Disorders
Interventions: ALD403, Placebo; Drug
Lead sponsor: Alder Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 898 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 73 more

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
Interventions: 200 mg Pembrolizumab, 350 mg Cemiplimab, ASP-1929 PIT; Biological · Combination Product
Lead sponsor: Rakuten Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Miami, Florida • Lexington, Kentucky • Rochester, Minnesota + 4 more

Conditions: Endometrial Cancer
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, megestrol acetate, paclitaxel, tamoxifen citrate; Biological · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 49
States / cities: Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 41 more

Conditions: Malignant Female Reproductive System Neoplasm
Interventions: Hydromorphone, Laparotomy, Liposomal Bupivacaine, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Seasonal Allergic Rhinitis
Interventions: azelastine hydrochloride 0.15% Nasal Spray, azelastine hydrochloride 0.15% and Placebo, Azelastine 0.1%, Nasal Spray; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 30
States / cities: Fountain Valley, California • Long Beach, California • Los Angeles, California + 26 more

Conditions: Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: tipifarnib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Coronary Syndrome
Interventions: Decision Aid; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cancer-related Problem/Condition, Head and Neck Cancer, Pain
Interventions: glutamine, radiation therapy, l-glutamine placebo; Dietary Supplement · Radiation · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 90 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 106
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 68 more

Conditions: Leukemia
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, tacrolimus, laboratory biomarker analysis, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation; Biological · Drug · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more

Conditions: Ventricular Arrythmia, Ventricular Fibrillation, Ventricular Tachycardia
Interventions: Atala™ lead and EV-ICD Pulse Generator; Device
Lead sponsor: AtaCor Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 27
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • La Jolla, California + 23 more

Conditions: Macular Edema
Interventions: Ranibizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 42
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 38 more

Conditions: Diabetes Mellitus, Type 1
Interventions: CGM and Insulin Pump, Closed-Loop Control System; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 3
States / cities: Santa Barbara, California • Rochester, Minnesota • Charlottesville, Virginia

Conditions: Thoracic Diseases, Lung Cancer, Lung Transplant
Interventions: Tissue Banking; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heart Failure
Interventions: Frailty assessment, Quality of life assessment; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive
Interventions: Bezuclastinib; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • Normal, Illinois + 17 more

Conditions: Pre-Bronchiolitis Obliterans Syndrome
Interventions: ARINA-1, Standard of care only; Drug · Other
Lead sponsor: Renovion, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more

Conditions: Congestive Heart Failure
Interventions: BodyGuardian remote health monitoring system; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer

Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies

Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Impact of a Decision Aid on Patient Decision Making in Emergency Department Chest Pain Patients

S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting

Thoracic Specimen Registry

The Utility of Focused Frailty Interventions on Patients With Advanced Heart Failure

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

Assessment of the BodyGuardian Remote Monitoring Platform in Elderly Healthy Subjects